	US 11,666,589 B2
	Pivarubicin and benzarubicin compositions
Leonard Lothstein, Eads, TN (US); Judith Soberman, Eads, TN (US); and Tiffany N. Seagroves, Memphis, TN (US)
Filed by Paradox Pharmaceuticals, Inc., Memphis, TN (US)
Filed on Mar. 2, 2021, as Appl. No. 17/190,317.
Claims priority of provisional application 62/984,258, filed on Mar. 2, 2020.
Prior Publication US 2021/0268007 A1, Sep. 2, 2021
Int. Cl. A61K 31/704 (2006.01); A61K 47/14 (2017.01); A61P 35/00 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01)

CPC A61K 31/704 (2013.01) [A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61P 35/00 (2018.01)]

10 Claims

1. A composition comprising at least one of pivarubicin and benzarubicin, or a pharmaceutically acceptable salt thereof, and further comprising a nonionic surfactant,

wherein said nonionic surfactant comprises polyethyleneglycol (15)-hydroxystearate,

wherein said nonionic surfactant is present in an amount of 0.1 to 5%,

wherein said benzarubicin is present in an amount of about 0.5-3.0 mg/mL, and

wherein said pivarubicin is present in an amount of about 0.5-3.0 mg/mL.